<?xml version="1.0" encoding="UTF-8"?>
<p id="par0040">It is estimated that 185 million people are infected with HCV globally 
 <xref rid="bib0115" ref-type="bibr">[23]</xref>. Infected individuals have a 75–85% likelihood of developing chronic infection, which when left untreated can lead to liver cirrhosis and hepatocarcinoma 
 <xref rid="bib0120" ref-type="bibr">[24]</xref>. Previous to 2011 [when the first direct-acting antivirals (DAAs) were released into the market], pegylated interferon (IFN)-α combined with ribavirin was used as a standard therapy, with aviraemia 24 weeks after completion of antiviral therapy of 40–80%, depending on viral genotype 
 <xref rid="bib0125" ref-type="bibr">[25]</xref>.
</p>
